Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Mar 20, 2025
Trial Information
Current as of April 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The TENDERS study is a clinical trial looking at how the timing of starting renal replacement therapy (RRT) affects patients with tumor lysis syndrome (TLS) who are experiencing acute kidney injury (AKI). TLS can happen after chemotherapy and can lead to serious imbalances in the body's chemicals, which may harm the kidneys. In this study, researchers will compare outcomes in patients who start RRT early versus those who start it later to see which approach leads to better kidney function after 30 days.
To participate in this trial, patients need to be adults aged 18 and older who are currently hospitalized in the ICU and have been diagnosed with a type of cancer that requires chemotherapy. They must also show signs of TLS based on specific laboratory tests. Patients and their families should know that this study is not yet recruiting participants, and those who join will help improve our understanding of the best timing for RRT in this critical situation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged ≥18 years.
- • Hospitalized in the ICU between January 1, 2013, and December 31, 2023.
- • Diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy.
- • Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation.
- Exclusion Criteria:
- • Patient or family opposition to data collection for research purposes.
- • Incomplete medical records that preclude data extraction.
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Angers, , France
Tours, , France
Orléans, , France
Bordeaux, , France
Brest, , France
Pau, , France
Limoges, , France
Nantes, , France
Rennes, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported